chevron-down Created with Sketch Beta.

ARTICLE

Merger Agreement Negotiations Under Trump 2.0: Spotlight on Antitrust Reverse Termination Fees

Jamillia P Ferris and Lindsey Edwards

Merger Agreement Negotiations Under Trump 2.0: Spotlight on Antitrust Reverse Termination Fees
Helder Faria via Getty Images

During the Biden administration, regulatory uncertainty for Hart-Scott-Rodino (“HSR”)-reportable transactions increased across industries. Antitrust risk historically has been a key consideration in merger agreement negotiations in deals between horizontal competitors in moderately or highly concentrated industries and deals between parties with a vertical relationship that could potentially harm one or both of their competitors post-merger. During the last four years, antitrust risk has become a more significant consideration in merger and acquisition (“M&A”) activity across the board as businesses tried to anticipate whether their transactions were likely to come under fire in the more aggressive merger enforcement regime championed by Federal Trade Commission (“FTC”) Chair Lina Khan and Assis-tant Attorney General for the Antitrust Division of the Department of Justice (“DOJ”) Jonathan Kanter. Antitrust practitioners advising M&A clients had to consider theories of harm beyond those traditionally pursued in modern merger enforcement, including conglomerate effects, impact on labor markets and wages, and “trends toward” concentration or vertical integration. The increased risk of regulatory scrutiny for these more novel theories of harm resulted in increased demand for reverse termination fees by sellers, leading to a steady rise in the percentage of merger agreements that contain such provisions.

As the business community adjusts to the second Trump administration, companies contemplating M&A activity will need to consider whether a change of course in negotiating reverse termination fees is warranted given new FTC and DOJ leadership. Sitting Commissioner Andrew Ferguson was elevated to FTC Chair in January and Gail Slater, a former advisor to Vice President JD Vance, was confirmed in March to lead the DOJ. Those leadership appointments, coupled with the active merger enforcement observed during Trump’s first term, suggest that the Trump FTC and DOJ may not simply adopt a laissez-faire approach to M&A as some commentators have suggested.

Ferguson and Slater have expressed more populist views on antitrust enforcement, particularly when it comes to regulating Big Tech. Ferguson has vowed to “hold big tech accountable and in Donald Trump’s announcement appointing Slater, he warned that “Big Tech has run wild for years, stifling competition in our most innovative sector and, as we all know, using its market power to crack down on the rights of so many Americans, as well as those of Little Tech! I was proud to fight these abuses in my First Term, and our [DOD’s] antitrust team will continue that work under Gail’s leadership.

One would ordinarily expect that a Republican Administration would cause the pendulum to swing back toward more “traditional” merger enforcement based on well-established theories of harm. Early indications suggest changes may not be as stark as one might think. Recall that just last year, JD Vance (advised by Slater at the time) complimented Lina Khan as “one of the few people in the Biden administration that I think is doing a pretty good job.” Both Ferguson and Slater have stated that the 2023 Merger Guidelines and the revised HSR Rules promulgated under the Biden administration will remain in effect, substantially increasing the burden on parties engaging in HSR-reportable transactions and leaving the door open to pursuing less conventional enforcement actions.

On the other hand, Ferguson’s agenda for the FTC includes “revers[ing] Lina Khan’s anti-business agenda” and stopping the “war on mergers.” His stated intention to “focus FTC resources on the mergers that harm competition and hinder innovation” is consistent with pursuing typical theories of harm against mergers that are likely to increase price or reduce output, quality, or innovation. Early statements also point to a return to utilizing settlements to resolve competitive concerns, whereas the Biden administration accepted substantially fewer settlements than prior Republican or Democratic ad-ministrations. During her confirmation hearing Slater was asked for assurance that the DOJ will “examine ways that we could ensure remedies or other alternatives before we charge in and go to court. She affirmed, noting that “often remedies, if done right, if they are robust— divestitures, for example—can remove anticompetitive harm from a merger in order to allow it to proceed in a pro-consumer, procompetitive manner.

There is also hope for a return to typical agency merger review procedures. Lina Khan was criticized for “throw[ing] sand into all the possible gears over proposed mergers, thereby halting many mergers by abuse of process and chilling other potential mergers from even being suggested. Both Ferguson and Republican Commissioner Melissa Holyoak have expressed concern about the FTC’s abuse of the merger review process as a means to deter M&A activity and achieve political objectives. Ferguson has stated that he and Holyoak engaged in “intense negotiations” with the Democratic Commissioners to lift the Biden administration’s ban on early termination—an important procedural feature whereby the FTC (and DOJ) inform merging parties that they are free to consummate transactions before the expiration of the statutory waiting period where the deals are quickly identified as presenting no competitive issues. Despite maintaining the burdensome HSR filing requirements voted out during the Biden administration, Ferguson has stated that the rules “will allow us to find anticompetitive mergers efficiently, while more quickly getting out of the way of deals that will benefit the American people. These statements alongside Ferguson’s commitment to “stop Lina Khan’s war on mergers” suggest that, at a minimum, deals will no longer face the headwinds prompted by a view that deals should die in the boardroom.

Antitrust Reverse Termination Fee Trends

Observed trends of the prevalence of reverse termination fees tied to a buyer’s obligation to obtain antitrust clearance for the deal (“Antitrust RTFs”)—considered alongside the other atmospheric changes referenced above—will inform how businesses think about, and how antitrust practitioners advise on, critical antitrust provisions in transaction negotiations over the next four years.

Antitrust RTFs historically were reserved for the small percentage of transactions that present the highest antitrust risk. During the Biden administration, however, the prevalence of Antitrust RTFs rose and ultimately surpassed levels observed during the Obama and first Trump administrations. As illustrated below, according to data obtained from Deal Point Data there was an increase in the percentage of transactions with an Antitrust RTF during the Obama administration, a slight decline during the first Trump administration, followed by a steady increase during the Biden administration culminating in over 13% of all transactions (and 22% of transactions with a public target) including an Antitrust RTF in 2024:

Percentage of Deals with Antitrust RTF (Public & Private Targets)

Percentage of Deals with Antitrust RTF (Public & Private Targets)

Percentage of Deals with Antitrust RTF (Public Targets Only)

Percentage of Deals with Antitrust RTF (Public Targets Only)

There are a number of factors that likely drove the heightened rate of transactions with Antitrust RTFs observed during the Biden administration. Deals that would have previously been considered to have low or moderate risk were more likely to be scrutinized due to the agencies’ aggressive investigation and enforcement of novel theories of harm. For example, the FTC challenged Amgen’s proposed acquisition of Horizon Therapeutics on the basis of a theory of harm that had not been asserted by the agencies in decades conglomerate effects. The FTC alleged that the deal would “entrench” Amgen’s dominant positions in certain markets, despite there being no economic relationship between the parties’ products in those markets. The agencies also demonstrated their unwillingness to entertain remedies to resolve competive concerns. This was a departure from prior administrations where the agencies touted their ability to resolve concerns while allowing procompetitive deals to proceed.

Further, many deals that would have been expected to close quickly and without concern under traditional antitrust analysis were increasingly subject to preliminary and extended investigations due to, for example, heightened interest in the industry they operated in or the identity of the buyer. The uncertainty generated by the increased likelihood of investigation was exacerbated by the procedural hurdles that extended the length of investigations.

The culmination of these factors significantly increased regulatory uncertainty for sellers, who sought ways to shift the risk of not being able to consummate the deal to the buyer. There are provisions other than Antitrust RTFs that would accomplish that goal, including hell or high water clauses or, short of that, commitments by the buyer to effectuate a remedy or defend through litigation any challenges initiated against the deal. However, the Biden agencies’ expressed hostility toward remedies and at least stated willingness to challenge mergers in federal court reduced the relative attractiveness of those clauses compared to Antitrust RTFs.

What to Expect Under Trump 2.0

Whether the prevalence of Antitrust RTFs will decline under the second Trump administration will depend on several possibilities, including whether the Trump FTC and DOJ will be more willing to accept remedies (which they have already signaled is likely); whether the profile of deals that become subject to extended investigations or enforcement actions will more closely mirror those challenged under traditional antitrust analysis; whether there will be fewer procedural hurdles allowing for more expeditious investigations; and whether certain industries or buyers continue to draw heightened scrutiny.

It is too early to determine the direction of travel for antitrust clauses under this administration. The business community will be watching the agencies closely over the coming year to ascertain the Trump FTC’s and DOJ’s merger policies in practice. Regardless of where the new administration lands ideologically, antitrust risk will remain an important driver in merger agreement negotiations. A close examination of the competitive landscape and any current or potential future overlaps between the merging parties’ products will continue to be a critical input into how attorneys advise clients during deal negotiations.

    Authors